ArticleAsian Pacific journal of cancer prevention : APJCP2026
Evaluation of Pathological Complete Response Rate in Patients with HER2-Positive Breast Cancer Undergoing Neoadjuvant Trastuzumab and Chemotherapy With or Without Anthracycline.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the pathological complete response rate (pCR) in HER2 breast cancer by comparing anthracycline-containing and anthracycline-free regimens.
methodsA retrospective cohort study was performed to obtain data from women undergoing neoadjuvant chemotherapy associated with two groups: • AC-TH patients: treated with trastuzumab with confirmed HER2-positive breast cancer using an anthracycline-based therapy followed by taxane. • CTH patients: recieved trastuzumab concurrently during taxane use in an anthracycline-free regime (carboplatin plus a taxane). Clinical data, pCR, free-disease survival, and overall survival were compared using chi-square, log-rank Mantel-cox, multinomial logistic and Cox regression tests (p < 0.05, SPSS v20.0).
resultsThere are no differences between AC-TH and CTH in terms of: • pCR (p=0.745), •Disease- free survival (p=0.840), • Overall survival (p=0.642). The major prognostic factor for overall survival were: • Nodal metastasis (p=0.043, HR = 0.263 (CI95% = 0.072-0.959) and • Dose reduction (p=0.021, HR = 0.070 (CI95% = 0.007-0.667) and For disease-free survival: • Age (p=0.038, HR = 3.288, CI95% 1.068-10.123) and • pCR (p=0.028, HR = 0.354, CI95% = 0.140-0.895). AC-TH showed more cardiotoxicity (9.3% vs 3.4%).
conclusionChemotherapy regimens with or without anthracycline, when combined with trastuzumab, demonstrate similar rates of pathological complete response and recurrence-free survival. Pathological complete response and age are independent variables associated with recurrence. However, the use of anthracycline leads to increased cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.